Design, synthesis and receptor affinity of novel conformationally restricted σ ligands based on the [4.3.3]propellane scaffold

European Journal of Medicinal Chemistry

Volumn 70, Issue , 2013, Pages 78-87

  Torres Gómez, Héctor ^a   Lehmkuhl, Kirstin ^a   Schepmann, Dirk ^a   Wünsch, Bernhard ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Conformational restriction; Pharmacophore models; Stereoselective reduction; 4.3.3 Propellane; Ligands

Indexed keywords

(ANTI 11 OXO[4.3.3] PROPELLAN 8 YL) N (2 METHOXY 5 METHYLPHENYL)CARBAMATE; (SYN 11 OXO[4.3.3]PROPELLAN 8 YL) N (2 METHOXY 5 METHYLPHENYL)CARBAMATE; ANTI 11 HYDROXY[4.3.3]PROPELLAN 8 ONE; HYDROCARBON; SYN 11 HYDROXY[4.3.3]PROPELLAN 8 ONE; TETRAMETHYL 8,11 DIOXO[4.3.3]PROPELLANE 7,9,10,12 TETRACARBOXYLATE; UNCLASSIFIED DRUG; [(8 ANTI 11 ANTI) (11 BENZYLAMINO)[4.3.3]PROPELLAN 8 YL] N (2 METHOXY 5 METHYLPHENYL)CARBAMATE; [(8 ANTI 11 ANTI) 11 HYDROXY[4.3.3]PROPELLAN 8 YL] N (2 METHOXY 5 METHYLPHENYL)CARBAMATE; [(8 ANTI 11 SYN) 11 HYDROXY[4.3.3]PROPELLAN 8 YL] N (2 METHOXY 5 METHYLPHENYL)CARBAMATE; [(8 ANTI 11 SYNI) (11 BENZYLAMINO)[4.3.3]PROPELLAN 8 YL] N (2 METHOXY 5 METHYLPHENYL)CARBAMATE; [(8 SYN 11 ANTI) (11 BENZYLAMINO)[4.3.3]PROPELLAN 8 YL] N (2 METHOXY 5 METHYLPHENYL)CARBAMATE; [(8 SYN 11 ANTI) 11 HYDROXY[4.3.3]PROPELLAN 8 YL] N (2 METHOXY 5 METHYLPHENYL)CARBAMATE; [(8 SYN 11 SYN) (11 BENZYLAMINO)[4.3.3]PROPELLAN 8 YL] N (2 METHOXY 5 METHYLPHENYL)CARBAMATE; [(8 SYN 11 SYN) 11 HYDROXY[4.3.3]PROPELLAN 8 YL] N (2 METHOXY 5 METHYLPHENYL)CARBAMATE; [4.3.3]PROPELLANE 8,11 DIONE;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; DIASTEREOISOMER; DRUG DESIGN; DRUG SYNTHESIS; MOLECULAR MODEL; NONHUMAN; PHARMACOPHORE; PROTEIN DETERMINATION; RAT; RECEPTOR BINDING;

CONFORMATIONAL RESTRICTION; PHARMACOPHORE MODELS; STEREOSELECTIVE REDUCTION; [4.3.3]PROPELLANE; Σ LIGANDS;

ANIMALS; BRAIN; BRIDGED COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; GUINEA PIGS; LIGANDS; LIVER; MOLECULAR CONFORMATION; RATS; RECEPTORS, SIGMA; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84885519218     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.09.021     Document Type: Article

References (52)

1. J.M. Walker, W.D. Bowen, F.O. Walker, R.R. Matsumoto, B.R. de Costa, and K.C. Rice Pharmacol. Rev. 42 1990 355 402
2. R. Quirion, R. Chicheportiche, C.P. Contreras, K.M. Johnson, D. Lodge, S.W. Tam, J.H. Woods, and S.R. Zukin Trends Neurosci. 10 1987 444 446
3. X. Guitart, G. Codony, and X. Monroy Psychopharmacology 174 2004 301 319
4. S.A. Wolfe Jr., S.G. Culp, and E.B. De Souza Endocrinology 124 1989 1160 1172
5. M. Hanner, F.F. Moebius, A. Flandorfer, H.G. Knaus, J. Striessnig, E. Kempner, and H. Glossmann Proc. Natl. Acad. Sci. U. S. A. 93 1996 8072 8077
6. R. Kekuda, P.D. Prasad, Y.J. Fei, F.H. Leibach, and V. Ganapathy Biochem. Biophys. Res. Commun. 229 1996 553 558
7. J. Mei, and G. Pasternak Biochem. Pharmacol. 62 2001 349 355
8. P. Seth, Y.J. Fei, H.W. Li, W. Huang, F.H. Leibach, and V. Ganapathy J. Neurochem. 70 1998 922 931
9. E. Laurini, V. Dal Col, M.G. Mamolo, D. Zampieri, P. Posocco, M. Fermeglia, L. Vio, and S. Pricl ACS Med. Chem. Lett. 2 2011 834 839
10. E. Laurini, D. Marson, V. Dal Col, M. Fermeglia, M.G. Mamolo, D. Zampieri, L. Vio, and S. Pricl Mol. Pharmaceutics 9 2012 3107 3126
11. C. Meyer, D. Schepmann, S. Yanagisawa, J. Yamaguchi, V. Dal Col, E. Laurini, K. Itami, S. Pricl, and B. Wünsch J. Med. Chem. 55 2012 8047 8065
12. T. Hayashi, and T.P. Su CNS Drugs 18 2004 269 284
13. E.J. Cobos, J. Entrena, F.R. Nieto, C.M. Cendan, and E. DelPezo Curr. Pharmacol. 6 2008 344 366
14. T. Maurice, and T.P. Su Pharmacol. Ther. 124 2009 195 206
15. M. Ishikawa, and K. Hashimoto J. Recept. Ligand Channel Res. 3 2010 25 36
16. E. Falkenstein, C. Meyer, C. Eisen, P.C. Scriba, and M. Weling Biochem. Biophys. Res. Commun. 229 1996 86 89
17. J. Xu, C. Zeng, W. Chu, F. Pan, J.M. Rothfuss, F. Zhang, Z. Tu, D. Zhou, D. Zeng, S. Vangveravong, F. Johnston, D. Spitzer, K.C. Chang, R.S. Hotchkiss, W.G. Hawkins, K.T. Wheeler, and R.H. Mach Nat. Commun. 2 380 2011
18. W.T. Bem, G.E. Thomas, J.Y. Mamone, S.M. Homan, B.K. Levy, F.E. Johnson, and C.J. Coscia Cancer Res. 51 1991 6558 6562
19. B.J. Vilner, C.S. John, and W.D. Bowen Cancer Res. 55 1995 408 413
20. K.T. Wheeler, L.M. Wang, C.A. Wallen, S.R. Childers, J.M. Cline, P.C. Keng, and R.H. Mach Br. J. Cancer 82 2000 1223 1232
21. H. Kashiwagi, J.E. McDunn, P.O. Simon Jr., P.S. Goedegebuure, J. Xu, L. Jones, K. Chang, F. Johnson, K. Trinkaus, R.S. Hotchkiss, R.H. Mach, and W.G. Hawkins Mol. Cancer 6 2007 48
22. R.H. Mach, and K.T. Wheeler Cent. Nerv. Syst. Agents Med. Chem. 9 2009 230 245
23. N.A. Colabufo, C. Abate, M. Contino, C. Inglese, M. Niso, F. Berardi, and R. Perrone Bioorg. Med. Chem. Lett. 18 2008 1990 1993
24. C. Zeng, J. Rothfuss, J. Zhang, W. Chu, S. Vangveravong, Z. Tu, F. Pan, K.C. Chang, R. Hotchkiss, and R.H. Mach Br. J. Cancer 106 2012 693 701
25. H. Kashiwagi, J.E. McDunn, P.O. Simon Jr., P.S. Goedegebuure, S. Vangveravong, K. Chang, R.S. Hotchkiss, R.H. Mach, and W.G. Hawkins J. Transl. Med. 7 2009 24
26. K.W. Crawford, and W.D. Bowen Cancer Res. 62 2002 313 322
27. M.S. Ostenfeld, N. Fehrenbacher, M. Hoyer-Hansen, C. Thomsen, T. Farkas, and M. Jaattela Cancer Res. 65 2005 8975 8983
28. W. Chu, J. Xu, D. Zhou, F. Zhang, L.A. Jones, K.T. Wheelers, and R.H. Mach Bioorg. Med. Chem. 17 2009 1222 1231
29. R.A. Glennon Mini-Rev. Med. Chem. 5 2005 927 940
30. P. Cratteri, M.N. Romanelli, G. Cruciani, C. Bonaccini, and F. Melani J. Comput. Aided Mol. Des. 18 2004 361 364
31. D. Zampieri, M.G. Mamolo, E. Laurini, C. Florio, C. Zanette, M. Fermeglia, P. Posocco, M.S. Paneni, S. Pricl, and L. Vio J. Med. Chem. 52 2009 5380 5393
32. E. Laurini, D. Zampieri, M.G. Manolo, L. Vio, C. Zanette, C. Florio, P. Posocco, M. Fermeglia, and S. Pricl Bioorg. Med. Chem. Lett. 20 2010 2954 2957
33. R. Holl, C. Geiger, M. Nambo, K. Itami, D. Schepmann, and B. Wünsch Cent. Nerv. Syst. Agents Med. Chem. 9 2009 220 229
34. A. Natrajan, J.D. Ferrar, J.D. Hays, M. Khot, J. Colonell, W.J. Youngs, and C.N. Sukenik J. Org. Chem. 55 1990 2164 2169
35. J. Altman, E. Babad, J. Itzchaki, and D. Gingsburg Tetrahedron 1966 279 304 (Suppl. 8. Part 1)
36. M. Kimura, S. Kuwano, K. Shimada, R. Kamato, S. Yasuda, Y. Samaki, H. Fujikawa, K. Noda, Y. Taga, and K. Takagi Bull. Chem. Soc. Jpn. 79 2006 1793 1797
37. P. Debroy, S.V. Lindeman, and R. Rathore Org. Lett. 9 2007 4091 4094
38. G. Fráter, D. Helmlinger, and P. Kraft Helv. Chim. Acta 86 2003 678 696
39. M. Vamos, and Y. Kobayashi Tetrahedron 65 2009 5899 5903
40. N. Yamamoto, H. Fujii, T. Nemoto, R. Nakajima, S. Momen, N. Izumimoto, K. Hasebe, H. Mochizuki, and H. Nagase Bioorg. Med. Chem. Lett. 21 2011 4104 4107
41. U. Weiss, and J.M. Edwards Tetrahedron Lett. 47 1968 4885 4887
42. R.W. Weber, and J.M. Cook Can. J. Chem. 56 1978 189 192
43. Molecular Operating Environment (MOE), 2012.10 2012 Chemical Computing Group Inc. 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7
44. E. Perola, and P.S. Charifson J. Med. Chem. 47 2004 2499 2510
45. I. Chen, and N. Foloppe J. Chem. Inf. Model 48 2008 1773 1791
46. M.M. Bradford Anal. Biochem. 72 1976 248 254
47. C.M. Stoscheck Meth. Enzymol. 182 1990 50 68
48. Y. Cheng, and W.H. Prusoff Biochem. Pharmacol. 22 1973 3099 3108
49. D.L. De-Haven-Hudkins, L.C. Fleissner, and F.Y. Ford-Rice Eur. J. Pharmacol. Mol. Pharmacol. Sect. 227 1992 371 378
50. H. Mach, C.R. Smith, and S.R. Childers Life Sci. 57 1995 57 62
51. D.M. Ferguson, and D.J. Raber J. Am. Chem. Soc. 111 1989 4371 4378
52. T.A. Halgren J. Comput. Chem. 17 1996 490 516